Mode
Text Size
Log in / Sign up
N/A N=123 Randomized Quadruple-blind Treatment

Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects

Cognitive Aging

Enrolled (actual)
123
Serious AEs
4.1%
Results posted
Aug 2014
Primary outcome: Primary: Mean in the Prefrontal Executive Function Z-score (PEF6_6) — 0.121; 0.213; 0.270 Z-score — p=0.06

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Guanfacine (Drug); Placebo (Drug)
Age
Older Adult · 75+ yrs
Sex
All
Sponsor
Yale University
Primary completion
Aug 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean in the Prefrontal Executive Function Z-score (PEF6_6)
0.121; 0.213; 0.270 0.06
SECONDARY
Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)
4; 2; 3; 20; 22; 25 0.67
SECONDARY
Quality of Life (SF-36 MCS)
-0.618; -0.960; -0.083 0.65

Summary

This proposal aims to determine whether low does of the alpha-2A-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated cognitive functions in healthy elderly subjects.

Eligibility Criteria

Inclusion Criteria

Subjects enrolled will be nondemented, male and female individuals who meet the following inclusion criteria:

  • 75 years of age or older
  • Fluent in English
  • Stable medical condition for at least 4 weeks prior to Screening visit
  • Stable dose of non-excluded medications for at least 4 weeks prior to Screening visit

Exclusion Criteria

  • Dementia
  • Mild Cognitive Impairment (Amnestic MCI)
  • Clinically significant neurologic disease
  • Clinically significant or unstable medical conditions that would interfere with participation in the trial
  • Known hypersensitivity to guanfacine
  • History of alcohol or substance abuse or dependence within the past 5 years
  • Active major psychiatric disorders, including major depression
  • History of mental retardation
  • Significant abnormalities on clinical laboratories, ECG, or physical examination
  • Impairment of visual or auditory acuity sufficient to interfere with completion of study procedures
  • Education level < 6 years
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00935493). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search